Vanguard Global Advisers
DRUG

Vanguard Global Advisers’s Bright Minds Biosciences DRUG Stock Holding History

Vanguard Global Advisers’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$272K Buy
3,870
+812
+27% +$63.8K ﹤0.01% 2375
2026
Q1 		$223K Buy
+3,058
New +$246K ﹤0.01% 2389

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Global Advisers's DRUG Position: Q2 2026 in Review

Vanguard Global Advisers increased its Bright Minds Biosciences (DRUG) stake by 27% in Q2 2026, buying an estimated $63.8K and bringing the position to 3,870 shares worth $272K. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

Vanguard Global Advisers first reported a position in DRUG in Q1 2026 and has held it in 2 quarters since. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Vanguard Global Advisers held 3,870 shares of Bright Minds Biosciences worth $272K as of Q2 2026.
  • Vanguard Global Advisers bought 812 Bright Minds Biosciences shares in Q2 2026, an estimated $63.8K.
  • Bright Minds Biosciences made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2375 holding.
  • Vanguard Global Advisers first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.